PMDA drug package insert
ブロマゼパム錠1mg「サンド」
PMDA Prescription drug · サンド株式会社 · package insert Oct 1, 2024
Key facts
| Brand names | ブロマゼパム錠1mg「サンド」, ブロマゼパム錠2mg「サンド」, ブロマゼパム錠3mg「サンド」, ブロマゼパム錠5mg「サンド」 |
|---|---|
| Nonproprietary names | ブロマゼパム |
| Companies | 製造販売／サンド株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 精神神経用剤 |
| Therapeutic category codes | 871124 |
| YJ codes | 1124020F1041, 1124020F2056, 1124020F3044, 1124020F4059 |
| Approval numbers | 30100AMX00115000, 30100AMX00116000, 30100AMX00117000, 30100AMX00118000 |
| Package insert edition | 第1版 |
| Package insert date | Oct 1, 2024 |
| PMDA document key | 270428_1124020F1041_1 |
| PMDA company code | 270428 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: